Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Navidea Biopharmaceuticals (NAVB) May Double in 2013

Although shares of Navidea Biopharmaceuticals Inc (NYSEAMEX:NAVB) are relatively unchanged over the trailing-12-month period, ask shareholders and they’d probably consider Navidea’s performance a major disappointment.

That disappointment stems from a complete response letter, or CRL, received in September for the company’s lead diagnostic candidate, Lymphoseek. In that CRL, the Food and Drug Administration noted that there weren’t any problems with Lymphoseek’s efficacy or safety, but there existed areas that needed addressing with regard to its third-party manufacturer. Following the resubmission of Lymphoseek to the FDA two months ago, I believe now is the time to seriously consider an investment in Navidea for a number of reasons.

Cardinal Health, Inc.To begin with, the technology is not only life-changing, but it’s a marked improvement from what’s already on the market. In simple terms, Lymphoseek is an injectable agent used in external lymph-node imaging and intra-operative lymphatic mapping, or ILM, procedures to help physicians determine which lymph nodes are infected with cancer and which aren’t. Based on numerous comparative trials, Pharmalucence’s sulfur colloid injection produced considerably more false-negative responses than Lymphoseek, and is tainted by longer waiting times and site injection pain, as well as more significant adverse events like hypersensitivity and anaphylaxis. Lymphoseek offers uniform preparation and minimal false-negative responses, and it dramatically improved the adverse event profile.

Another important aspect you have to consider is the nature of the CRL — which was based on manufacturing, not efficacy or safety. Manufacturing snags are actually quite common these days, and rarely do they preclude a drug or diagnostic from eventual approval. MAP Pharmaceuticals Inc. (NASDAQ:MAPP)‘ inhaled migraine medication Levadex and Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA)‘ inhaled antipsycholtic drug Adasuve were both rejected because of manufacturing deficiencies. For MAP, its CRL was based on manufacturing process controls like product specifications and justification of process controls; however, its PDUFA date is rapidly approaching. In Alexza’s case, it was manufacturing deficiencies in its Mountain View, Calif., facility that pushed back Adasuve’s FDA approval from what would have been May 2012 all the way to late December.

The approval process may not appear smooth, but I’d project that an approval is coming at some point within the next year for Lymphoseek. Remember, as well, that Navidea has also submitted a Marketing Authorization Application with the European Medicines Agency.

Navidea’s commercial partnerships with Cardinal Health, Inc. (NYSE:CAH) can’t be overlooked, either. Cardinal Health will ultimately be in charge of Lymphoseek’s pricing — probably a smart move on Navidea’s part — and has the pharmacies and manufacturing capabilities to begin commercial production within weeks of a U.S. approval.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.